Training Example: BRILINTA – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

BRILINTA

(https://brilinta.com) 📸 Data Snapshot: May 29, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Treatment | ACS | Acute Ischemic Stroke | CAD | BRILINTA® (ticagrelor) tablets (https://brilinta.com)
Title

Treatment | ACS | Acute Ischemic Stroke | CAD | BRILINTA® (ticagrelor) tablets

Meta

BRILINTA® (ticagrelor) is an oral prescription indicated for treatment of acute ischemic stroke, coronary artery disease and acute coronary syndrome.

H2 WHO HAVE SURVIVED A HEART ATTACK
H2 WITH CAD AT HIGH RISK OF A FIRST HEART ATTACK OR STROKE
H2 WITH A STROKE (ACUTE ISCHEMIC STROKE)
H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS Read More
H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS
H3 FOR PEOPLE
H3 FOR PEOPLE
H3 FOR PEOPLE
H3 Approved Use
H3 APPROVED USE
HEADING_BODY Acute Coronary Syndrome (ACS) | BRILINTA® (ticagrelor) tablets (https://brilinta.com/acs.html)
Title

Acute Coronary Syndrome (ACS) | BRILINTA® (ticagrelor) tablets

Meta

BRILINTA® (ticagrelor) is a prescribed medicine used to treat people with acute coronary syndrome.

H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS Read More
H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS
H3 BRILINTA WORKED BETTER THAN PLAVIX
H3 PAY AS LOW AS $5 EACH MONTH FOR BRILINTA
H3 QUESTIONS TO ASK YOUR DOCTOR
H3 Approved Use
H3 APPROVED USE
HEADING_BODY Coronary Artery Disease (CAD) | BRILINTA® (ticagrelor) tablets (https://brilinta.com/cad.html)
Title

Coronary Artery Disease (CAD) | BRILINTA® (ticagrelor) tablets

Meta

Read about BRILINTA® (ticagrelor), an oral prescription treatment for people with coronary artery disease.

H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS Read More
H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS
H3 Coronary artery disease (CAD) is the most common form of heart disease in the United States. When people have CAD, plaque has built up in their heart's arteries and can affect the blood supply to their heart.
H3 IF YOU HAVE CAD AND ARE AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE, TALK TO YOUR DOCTOR TO SEE IF BRILINTA MAY BE A TREATMENT OPTION FOR YOU.
H3 In patients with CAD who are at high risk, BRILINTA is used to lower your chance of having a first heart attack or stroke.
H3 A MAJOR CLINICAL STUDY COMPARED BRILINTA 60 MG* TWICE DAILY + ASPIRIN ONCE DAILY VS PLACEBO + ASPIRIN ONCE DAILY FOR A MEDIAN OF 2.75 YEARS.
H3 BRILINTA 60 MG IS USED TO HELP REDUCE THE RISK OF A FIRST MI OR STROKE IN PATIENTS WITH CAD WHO ARE AT HIGH RISK.
H3 Eligible patients pay as low as $5†
H3 How to get your BRILINTA Savings Card
H3 Approved Use
H3 APPROVED USE
H4 DOWNLOAD THE CARD
H4 Savings Card Terms and Conditions
HEADING_BODY Acute Ischemic Stroke | BRILINTA® (ticagrelor) tablets (https://brilinta.com/stroke.html)
Title

Acute Ischemic Stroke | BRILINTA® (ticagrelor) tablets

Meta

Read about BRILINTA® (ticagrelor), an oral prescription indicated for the treatment of patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS Read More
H2 IMPORTANT SAFETY INFORMATION ABOUT BRILINTA® (ticagrelor), INCLUDING BOXED WARNING, FOR 60-MG AND 90-MG TABLETS
H3 Understanding Your Stroke
H3 BRILINTA IS USED TO LOWER THE RISK OF STROKE FOR PATIENTS WITH A STROKE (ACUTE ISCHEMIC STROKE) OR MINI-STROKE (TIA)
H3 IN A MAJOR CLINICAL STUDY, BRILINTA + ASPIRIN WORKED BETTER THAN ASPIRIN ALONE
H3 BRILINTA 90 MG + ASPIRIN WAS PROVEN TO HELP REDUCE THE RISK OF HAVING ANOTHER STROKE BETTER THAN ASPIRIN ALONE WITHIN THE FIRST 30 DAYS AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TIA (MINI-STROKE)
H3 SAVE WITH MEDICARE PART D
H3 Eligible patients pay as low as $5‡
H3 How to get your BRILINTA Savings Card
H3 Approved Use
H3 APPROVED USE
H4 DOWNLOAD THE CARD
H4 Savings Card Terms and Conditions
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE · THIN (https://brilinta.com) Treatment | ACS | Acute Ischemic Stroke | CAD | BRILINTA® (ticagrelor) tablets
BRILINTA is for people who have suffered a heart attack, have coronary artery disease (CAD) with a high risk of a first heart attack or stroke, or with a stroke (acute ischemic stroke).

[IMG: Acute Coronary Syndrome link]
[H3] FOR PEOPLE
[H2] WHO HAVE SURVIVED A HEART ATTACK

[IMG: Coronary Artery Disease link]
[H3] FOR PEOPLE
[H2] WITH CAD AT HIGH RISK OF A FIRST HEART ATTACK OR STROKE

[IMG: Coronary Artery Disease link]
[H3] FOR PEOPLE
[H2] WITH A STROKE (ACUTE ISCHEMIC STROKE)
565 chars
SUB-PAGE (https://brilinta.com/acs.html) Acute Coronary Syndrome (ACS) | BRILINTA® (ticagrelor) tablets
[IMG: Brilinta Savings Card]
*Commercially insured patients. Subject to eligibility rules. Restrictions apply.

[IMG: Save On Brilinta Now]

[H3] BRILINTA WORKED BETTER THAN PLAVIX
In a major clinical study, BRILINTA 90 mg + aspirin was proven to reduce the risk of another heart attack, or dying from one, better than Plavix + aspirin, for 12 months in patients who were recently hospitalized for a heart attack.
LEARN MORE

[H3] PAY AS LOW AS $5 EACH MONTH FOR BRILINTA
If you have commercial insurance, you may pay as low as $5 for BRILINTA. Subject to eligibility rules; restrictions apply.
SAVE ON BRILINTA

[H3] QUESTIONS TO ASK YOUR DOCTOR
Get a guide to help you talk with your doctor about your risk for another heart attack.
DOWNLOAD
863 chars
SUB-PAGE (https://brilinta.com/cad.html) Coronary Artery Disease (CAD) | BRILINTA® (ticagrelor) tablets
About Coronary Artery Disease
About BRILINTA
Saving With BRILINTA
Choose Condition
Acute Coronary Syndrome
Coronary Artery Disease
Stroke (acute ischemic stroke)
Health Care Professional Site
BRILINTA Facebook

[IMG: About Coronary Artery Disease]

[H3] Coronary artery disease (CAD) is the most common form of heart disease in the United States. When people have CAD, plaque has built up in their heart's arteries and can affect the blood supply to their heart.

People who meet any of the following criteria may be at an increased risk for CAD:
High blood pressure
High cholesterol
Diabetes or insulin resistance
Obesity
Smoker

[H3] IF YOU HAVE CAD AND ARE AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE, TALK TO YOUR DOCTOR TO SEE IF BRILINTA MAY BE A TREATMENT OPTION FOR YOU.

Back to Top

[IMG: About BRILINTA® (ticagrelor)]

[H3] In patients with CAD who are at high risk, BRILINTA is used to lower your chance of having a first heart attack or stroke.

TAP TO SEE IT WITHOUT BRILINTA

BRILINTA is an oral medication that helps stop platelets from sticking together and forming a clot that could cause a first heart attack or stroke.
BRILINTA 60 mg is taken twice a day—1 tablet in the morning and 1 tablet in the evening. Take only one 81-mg aspirin once daily.

[H3] A MAJOR CLINICAL STUDY COMPARED BRILINTA 60 MG* TWICE DAILY + ASPIRIN ONCE DAILY VS PLACEBO + ASPIRIN ONCE DAILY FOR A MEDIAN OF 2.75 YEARS.

This study included over 19,000 patients

Patients with CAD were considered to be at high cardiovascular risk based on their risk factors*

Patients were studied for a median of 2.75 years

*Patients included in the study were ≥50 years old, had coronary artery disease (defined as a history of a stent in a coronary artery, heart bypass surgery, or a ≥50% blockage in at least one of their coronary arteries), and had type 2 diabetes treated for at least 6 months with blood–sugar–lowering medication.

[H3] BRILINTA 60 MG IS USED TO HELP REDUCE THE RISK OF A FIRST MI OR STROKE IN PATIENTS WITH CAD WHO ARE AT HIGH RISK.

Back to Top

[IMG: Saving with BRILINTA® (ticagrelor)]

[IMG: BRILINTA® (ticagrelor) Savings Card]

[H3] Eligible patients pay as low as $5†
With the BRILINTA Savings Card, your monthly cost for BRILINTA could be as low as $5† each month. If you have commercial insurance, you may be eligible. Commercial insurance is sometimes referred to as "private insurance" and is typically provided by the company you work for.

†Commercially insured patients. Eligible patients will pay as low as $5 for each 30-day supply for as long as their doctor prescribes BRILINTA, subject to a maximum savings of $200 per 30-day supply. Subject to eligibility rules below; restrictions apply.

[H3] How to get your BRILINTA Savings Card
Download the Savings Card to start saving on your prescription of BRILINTA.

[H4] DOWNLOAD THE CARD
Download and print the Savings Card now.

DOWNLOAD

Back to Top

[H4] Savings Card Terms and Conditions
ELIGIBILITY: You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions. Patients who are enrolled in a state- or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare-eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. If you are enrolled in a state- or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico.
TERMS OF USE: Eligible commercially insured/covered patients with no restrictions (step-edit, prior authorization, or NDC block) and a valid prescription for BRILINTA® (ticagrelor) tablets who present this Savings Card at participating pharmacies will pay as low as $5 per 30-day supply. A $200 maximum savings limit applies; patient’s out-of-pocket expense may vary. If you are insured and your insurance does not cover or has a managed-care restriction on your prescription (step-edit, prior authorization, or NDC block), you will pay as low as $5 per 30-day supply. If you pay cash for your prescription, AstraZeneca will pay up to the first $100 per month, and you will be responsible for any remaining balance, for each monthly prescription. Other restrictions may apply. Patient is responsible for applicable taxes, if any. Nontransferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed, or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility, and terms of use at any time without notice. This offer is not conditioned on any past, present, or future purchase, including refills. Offer must be presented along with a valid prescription at the time of purchase. For additional details about this offer, please visit www.brilinta.com. If you have any questions regarding this offer, please call 1-800-422-5604.
BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
Pharmacist Instructions for a Patient With an Eligible Third-Party Payer:
For Commercially Insured/Covered Patients: Submit the claim to the primary Third-Party Payer first, then submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. This will reduce the eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit of $200 for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for Insured/Not Covered Patients: Submit the claim to the primary Third-Party Payer first; if the primary claim submission shows a managed-care restriction (step-edit, prior authorization, or NDC block), continue the claim adjudication process and submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 3. This will reduce eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for a Cash-Paying Patient: Submit this claim to Change Healthcare. A valid Other Coverage Code (eg, 1) is required. The card may cover up to a maximum of $100 per each 30-day supply. Reimbursement will be received from Change Healthcare. For any questions regarding Change Healthcare online processing, please call the Help Desk at 1-800-422-5604.Program managed by ConnectiveRx on behalf of AstraZeneca.
7617 chars
SUB-PAGE (https://brilinta.com/stroke.html) Acute Ischemic Stroke | BRILINTA® (ticagrelor) tablets
About Stroke (acute ischemic stroke)
About BRILINTA
Saving With BRILINTA
Choose Condition
Acute Coronary Syndrome
Coronary Artery Disease
Stroke (acute ischemic stroke)
Health Care Professional Site
BRILINTA Facebook

[IMG: About Acute Ischemic Stroke]

IN THE MONTH FOLLOWING AN ACUTE ISCHEMIC STROKE, PATIENTS MAY BE AT RISK OF HAVING ANOTHER STROKE. LEARN HOW TO HELP REDUCE THE RISK OF ANOTHER STROKE.
[H3] Understanding Your Stroke
Surviving an acute ischemic stroke is a life-changing experience. Although your stroke was unexpected, it's important that you and your loved ones understand that a stroke may not be a one-time event.
Your stroke may have been caused by plaque rupturing in an artery, which caused platelets to become activated, stick together, and block the flow of blood and oxygen to the brain.

Plaque is mostly made up of fat, cholesterol, and other substances found in your blood. In the first 30 days after an acute ischemic stroke, you may be at risk of having another stroke.
To help reduce your risk of another stroke, your doctor will recommend a treatment plan and lifestyle changes that may apply to you. These could include:
changes in diet
changes in exercise
changes in habits, like smoking
Back to Top

[IMG: About BRILINTA® (ticagrelor)]

[H3] BRILINTA IS USED TO LOWER THE RISK OF STROKE FOR PATIENTS WITH A STROKE (ACUTE ISCHEMIC STROKE) OR MINI-STROKE (TIA)

BRILINTA is a type of medicine known as an oral antiplatelet (OAP). It helps stop platelets from sticking together and forming a clot.

[H3] IN A MAJOR CLINICAL STUDY, BRILINTA + ASPIRIN WORKED BETTER THAN ASPIRIN ALONE

This study included over 11,000 patients

Patients also took other medications commonly prescribed after a stroke

The study began within 24 hours of the acute ischemic stroke or high-risk TIA (mini-stroke) and patients were treated for up to 30 days

[H3] BRILINTA 90 MG + ASPIRIN WAS PROVEN TO HELP REDUCE THE RISK OF HAVING ANOTHER STROKE BETTER THAN ASPIRIN ALONE WITHIN THE FIRST 30 DAYS AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TIA (MINI-STROKE)

Back to Top

[IMG: Saving with BRILINTA® (ticagrelor)]

[IMG: Medicare Part D]
[H3] SAVE WITH MEDICARE PART D
Majority of Medicare Part D Patients* will have a copay of less than $45† per month.
*“Patients” means covered lives (EGWP, Medicare MA, Medicare PDP, Medicare SN, Medi-Medi, PACE) at tiers 1-7 nationwide as calculated by Fingertip Formulary® data accessed on 2/16/2021. Cost comparisons do not imply comparable efficacy, safety, or FDA-approved indications.
†Subject to eligibility rules. Restrictions apply.

[IMG: BRILINTA® (ticagrelor) Savings Card]
[H3] Eligible patients pay as low as $5‡
With the BRILINTA Savings Card, your monthly cost for BRILINTA could be as low as $5‡ each month. If you have commercial insurance, you may be eligible. Commercial insurance is sometimes referred to as "private insurance" and is typically provided by the company you work for.
‡Commercially insured patients. Eligible patients will pay as low as $5 for each 30-day supply for as long as their doctor prescribes BRILINTA, subject to a maximum savings of $200 per 30-day supply. Subject to eligibility rules below; restrictions apply.

[H3] How to get your BRILINTA Savings Card
Download the Savings Card to start saving on your prescription of BRILINTA.
[H4] DOWNLOAD THE CARD
Download and print the Savings Card now.
DOWNLOAD
Back to Top

[H4] Savings Card Terms and Conditions
ELIGIBILITY: You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions. Patients who are enrolled in a state- or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare-eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. If you are enrolled in a state- or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico.
TERMS OF USE: Eligible commercially insured/covered patients with no restrictions (step-edit, prior authorization, or NDC block) and a valid prescription for BRILINTA® (ticagrelor) tablets who present this Savings Card at participating pharmacies will pay as low as $5 per 30-day supply. A $200 maximum savings limit applies; patient’s out-of-pocket expense may vary. If you are insured and your insurance does not cover or has a managed-care restriction on your prescription (step-edit, prior authorization, or NDC block), you will pay as low as $5 per 30-day supply. If you pay cash for your prescription, AstraZeneca will pay up to the first $100 per month, and you will be responsible for any remaining balance, for each monthly prescription. Other restrictions may apply. Patient is responsible for applicable taxes, if any. Nontransferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed, or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility, and terms of use at any time without notice. This offer is not conditioned on any past, present, or future purchase, including refills. Offer must be presented along with a valid prescription at the time of purchase. For additional details about this offer, please visit www.brilinta.com. If you have any questions regarding this offer, please call 1-800-422-5604.
BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
Pharmacist Instructions for a Patient With an Eligible Third-Party Payer:
For Commercially Insured/Covered Patients: Submit the claim to the primary Third-Party Payer first, then submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. This will reduce the eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit of $200 for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for Insured/Not Covered Patients: Submit the claim to the primary Third-Party Payer first; if the primary claim submission shows a managed-care restriction (step-edit, prior authorization, or NDC block), continue the claim adjudication process and submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 3. This will reduce eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for a Cash-Paying Patient: Submit this claim to Change Healthcare. A valid Other Coverage Code (eg, 1) is required. The card may cover up to a maximum of $100 per each 30-day supply. Reimbursement will be received from Change Healthcare. For any questions regarding Change Healthcare online processing, please call the Help Desk at 1-800-422-5604.Program managed by ConnectiveRx on behalf of AstraZeneca.
8082 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
6External proof links (all pages)
PageReviewsProof links
/ (home) 0 1
/acs.html 0 1
/cad.html 0 2
/stroke.html 0 2
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/acs.html — no schema detected (entity gap)
/cad.html — no schema detected (entity gap)
/stroke.html — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: BRILINTA (brilinta.com)

https://brilinta.com 📍 Industry: Medical Devices, Pharma & Biotech
31 BS / 100

This is a low-BS pharmaceutical site that prioritizes clinical data over creative marketing. While the technical SEO and schema implementation are non-existent, the forensic evidence (patient counts, median trial lengths, specific indications) proves significant substance behind the drug’s claims.

Info Density Power-words vs. Substance ratio.
5
17% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
1
5% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
7
35% BS
Commodity Fingerprint Detection of industry clichés/templates.
6
40% BS
Identity & Authority Expert verifiability & Schema depth.
12
80% BS

Implement H1 tags on all pages to clearly define indications (e.g., ‘BRILINTA for Acute Ischemic Stroke’). Deploy MedicalWebPage and Drug schema to provide technical authority and link to the brand’s AstraZeneca heritage. Update the Medicare formulary data, which is currently over five years old. Add direct outbound citations to the peer-reviewed clinical publications for the PLATO and PEGASUS trials.

The site content confirms a high-fidelity match with the Pharma and Biotech industry, specifically focusing on cardiovascular therapeutic areas. The presence of ‘Boxed Warnings,’ ‘Safety Information,’ and comparative clinical trial data (ticagrelor vs. clopidogrel/Plavix) is consistent with FDA-regulated pharmaceutical communication.

“The BS score of 31 is driven by a lack of structured data and technical SEO failures (Pillar 5) and the use of stale financial evidence (Pillar 3). It remains low overall because the site avoids marketing hyperbole and provides verifiable clinical metrics for every primary claim.”

Verified Analysis Date: May 29, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation